Johnson & Johnson 8-K (2.02, 9.01): reported results of operations

Johnson & Johnson reported third-quarter 2026 sales of $25.4 billion, up 5.9%, and diluted EPS of $0.09; adjusted EPS was $2.59, and it raised its 2026 guidance, projecting $101.2 billion in reported sales and adjusted EPS of $11.10.